Erectile Dysfunction 1.
Rosen R, Altwein J, Boyle P, et al., Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7), Eur Urol, 2003:44;637–49.
2.
Blanker MH, Bohnen AM, Groeneveld FP, et al., Correlates for erectile and ejaculatory dysfunction in older Dutch men: A community-based study, J Am Geriatr Soc, 2001:49;436–42.
3.
Carraro JC, Raynaud JP, Koch G, et al., Comparison of phytotherapy with finasteride in the treatment of BPH: a randomised international study of 1,098 patients, Prostate, 1998:29;231–40.
4.
Boyle P, Gould AL, Roehrborn CG, Prostate volume predicts outcome of treatment in BPH with finasteride: a Meta-analysis of randomised clinical trials, Urology, 1996;48:398–405.
5. 6.
Andriole GL, Kirby R, Safety and tolerability of the dual 5alpha-reductasa inhibitor dutasteride in the treatment of BPH, Eur Urol, 2003;44:82–8.
Roehrborn CG, Boyle P, Nickel JC, et al., ARIA3001, ARIA 3002 and ARIA 3003 study investigators. Efficacy and safety of a dual inhibitor of 5alpha-reductase types 1 and 2 (Dutasteride) in men with BPH, Urology, 2002;60:434–41.
7.
Lowe FC, McConell JD, Hudson PB, et al., Long term 6-year experience with Finasteride in patients with BPH, Urology, 2003;61:791–6.
8. Schulman CC, Lower urinary tract symptoms/Benign prostatic hyperplasia: minimizing morbidity caused by treatment, Urology, 2003;62:24–33.
9.
McConnell JD, Roehrborn CG, Bautista OM, et al., Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia, N Engl J Med, 2003;349(25):2387–98.
10. 11.
AUA Practice Guidelines Committee, AUA guideline on management of BPH(2003). Chapter 1: Diagnosis and treatment recommendations, J Urol, 2003;170:530–47.
Lepor H, Williford WO, Barry MJ, et al., The efficacy of Terazosin, Finasteride, or both in BPH. Veterans affairs cooperative studies BPH study group, N Engl J Med, 1996;335:533–9.
12. 13.
Roehrborn CG, Marks LS, Fenter T, et al., Efficacy and safety of Dutasteride in the four year treatment of men with BPH, Urology, 2004;63:709–15.
Roehrborn CG, Boyle P, Nickel JC, et al., ARIA3001, ARIA 3002 and ARIA 3003 study investigators. Efficacy and safety of a dual inhibitor of 5alpha-reductase types 1 and 2 (Dutasteride) in men with BPH, Urology, 2002;60:434–41.
14. 15.
Eri LM, Tueter KJ, Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia, J Urol, 1995;154:923–34.
Buzelin JM, Roth S, Geffriaud-Riconard C, et al., Efficacy and safety of sustained released alfuzosin 5 mg in patients with BPH. ALGEBI study group, Eur Urol, 1997;31: 190–98.
16.
Witte DG, Brune ME, Katwala SP, et al., Relationships between pharmacokinetics of agonist-induced prostatic pressure and mean arterial pressure in the conscious dog after single and repeated daily oral administration of terazosin, J Pharmacol Exp Ther, 1997;282:891–8.
17.
Höfner K, Claes H, De Reijke TM, et al., the European Tamsulosin Study Group. Tamsulosin 0.4mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction, Eur Urol, 1999;36:335–41.
18.
Lukacs B, Grange JC, McCarthy C, Comet D, Clinical uroselectivity: a 3-year follow-up in general practice. BPH
27. 28. 29. 30. 31. 24. 25. 26. group in general practice, Eur Urol, 1998;2:28–33. 19.
Rosen R, Seftel A, Roehrborn CG, Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia, Int J Impot Res, 2007;19:480–85.
20. 21.
Andersson KE, Syief CG, Neurotransmission at the contraction and relaxation of penile erectile tissues, World J Urol, 1997;15:14–20.
Rosen RC, Wei JT, Althof SE, et al., BPH Registry and Patient Survey Steering Committee. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry, Urology, 2009;73:562–6.
22. 23.
Roehrborn CG, Acute urinary retention: Risks and management, Rev Urol, 2005;7:31–41.
Roehrborn CG, Siami P, Barkin J, et al., CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: four-year results from the CombAT study, Eur Urol, 2010;57:123–31.
Finkle AL, Moyers TG, Sexual potency in aging males: status of private patients before and after prostatectomy, J Urol, 1960;84:152–7.
Altwein JE, Keuler FU, BPH and erectile dysfunction: a review, Urol Int, 1992;48:53–7.
Tscholl R, Largo M, Poppinghaus E, et al., Incidence of erectile impotence secondary to transurethral resection of BPH, assessed by pre- and post-operative snap gauges tests, J Urol, 1995;153:1491–3.
De Backer E, Lauwerijins A, Willem C, Sexual behavior after prostatectomy, Eur Urol, 1997;3;295–8.
So EP, Ho PC, Bodenstab W, et al., Erectile impotence associates with transurethral prostatectomy, Urology, 1982;19:259–62.
Soderdahl DW, Knight RW, Hansberry KL, Erectile dysfunction following transurethral resection of the prostate, J Urol, 1996;156:1354–6.
Lindner A, Golomb J, Korzcak D, et al., Effects of prostatectomy on sexual function, Urology, 1991;38:26–8.
Bieri S, Iselin CE, Rohner S, Capsular perforation localization and adenoma size as prognostic indicators of erectile dysfunction after transurethral prostatectomy, Scand J Urol Nephrol, 1997;31:545–8.
32. 33. 34. 35.
Hanbury DC, Sethia KK, Erectile function following transurethral prostatectomy, Br J Urol, 1995;75:12–13.
Martínez-Jabaloyas JM, Villamón-Fort R, Gil-Salom M, Chuan-Nuez P, Impact of benign prostatic hyperplasia surgery on erectile function, Urol Int, 2010;84:407–12.
Kassabian VS, Sexual function in patients treated for BPH, Lancet, 2003; 361:60–62.
Brookes ST, Donovan JL, Peters TJ, et al., Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial, BMJ, 2002;324:1059–61.
36. 37. 38.
Vale J, BPH an erectile dysfunction – is there a link?, Curr Med Res Opin, 2000;(Suppl. 16):63–7.
Perera ND, Hill JT, Erectile and ejaculatory failure after transurethral prostatectomy, Ceylon Med J, 1998;43:74–7.
Mebust WK, Holtgrewe HL, Cockett AT, Transurethral prostatectomy: immediate and post-operative complications. A co-operative study of 13 participating institutions evaluating 3885 patients, J Urol, 1989;141: 243–7.
39. 40.
Taher A, Erectile dysfunction after TURP: incidence and risk factors, World J Urol, 2004;22:457–60.
Parsons CI, Impotence following transurethral resections of the prostate. In: Raijfer J (ed.), Common problems in
55. 56. 57. 52. 53. 51. 49. 48. 45. 46. 41.
infertility and impotence, Chicago: Year Book Medical, 1990:352–5.
Vallancien G, Emberton M, Harving N, Van Moorselar RJ, Alf-One study group. Sexual dysfunction in 1274 european men suffering from low urinary tract symptoms, J Urol, 2003;169:2257–61.
42.
Franco G, De Nuncio C, Federico G, Evaluation of sexual activity after prostatic surgery for BPH assessed by pre-operative and post-operative questionnaire, Minerva Urol Nefrol, 2005;57:331–4.
43. 44.
Mishriki SF, Cohen NP, Mawas A, et al., TURP can improve your sex life, J Urol, 2001;165:36.
Riehman M, Knes JM, Heisey D, et al., Transurethral resection versus incision of the prostate: a randomised, prospective study, Urology, 1995;45:768–75.
Oesterling JE, Retropubic and suprapubic prostatectomy. In: Walsh PC (ed.), Campbell’s Urology 7th edition, Philadelphia: WB Saunders, 1998:1529–41.
Gilling PJ, Kennet KM, Fraundorfer MR, Holmium laser enucleation of the prostate glands larger than 100gr: an endourologic alternative to open prostatectomy, J Endourol, 2000;14:529–31.
47.
Briganti, Naspro R, Gallina A, et al., Impact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2-center, randomised trial, J Urol, 2006;175: 1817–21.
Naspro R, Suardi N, Salonia A, et al., Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24-month follow-up, Eur Urol, 2006;50:563–8.
Paick JS, Um JM, Kim SW, Influence of high-power potassium-titanyl-phosphate photoselective vaporisation of the prostate on erectile function: a short-term follow-up study, J Sex Med, 2007;4:1701–7.
50.
Alivizatos G, Skolarikos A, Chalikopoulos D, et al., Transurethral photoselective vaporisation versus transvesical open enucleation for prostatic adenomas >80 ml: 12-months results of a randomised prospective study, Eur Urol, 2008;54:427–37.
Dahlstrand C, Walden M, Geirsson G, Transurethral microwave thermotherapy versus transurethral resection for symptomatic benign prostate obstruction: a prospective randomised study with a 2-year follow-up, Br J Urol, 1995;76:614–18.
Tsai YS, Lin JS, Tong JC, et al., Transurethral microwave thermotherapy for symptomatic BPH: long-term durability with prostcare, Eur Urol, 2001;39:688–92.
Francisca EAE, et al., Quality of life assessement in patients treated with lower energy thermotherapy (Prostasoft 2.0). Results of a randomised transurethral microwave thermotherapy versus sham study, J Urol, 1997;158:1839–44.
54.
Bruskewitz R, Issa MM, Roehrborn CG, et al., A prospective, randomised, 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic BPH, J Urol, 1998;159:1588–93.
Schulman CC, Zlotta AR, Transurethral needle ablation of the prostate for treatment of BPH: early clinical experience, Urology, 1995;45:28–33.
Steele GS, Sleep DJ, Transuethral needele ablation of the prostate: a urodynamic based study with 2-year follow-up, J Urol, 1997;158:1834–8.
Roehrborn CG, et al., Transurethral needle ablation for BPH: 12-month results of a prospective, multicentre US study, Urology, 1998;51:415–21.
54
EUROPEAN UROLOGICAL REVIEW
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84